참고문헌
- Abu El-Naaj I, Leiser Y, Wolff A, Peled M. The surgical management of rhinocerebral mucormycosis. J Craniomaxillofac Surg 2013;41:291-5. https://doi.org/10.1016/j.jcms.2012.03.019
- Mantadakis E, Samonis G. Clinical presentation of zygomycosis. Clin Microbiol Infect 2009;15(Suppl 5):15-20.
- Dhiwakar M, Thakar A, Bahadur S. Improving outcomes in rhinocerebral mucormycosis--early diagnostic pointers and prognostic factors. J Laryngol Otol 2003;117:861-5.
- Bitar D, Van Cauteren D, Lanternier F, Dannaoui E, Che D, Dromer F, et al. Increasing incidence of zygomycosis (mucormycosis), France, 1997-2006. Emerg Infect Dis 2009;15:1395-401. https://doi.org/10.3201/eid1509.090334
- Rammaert B, Lanternier F, Poirée S, Kania R, Lortholary O. Diabetes and mucormycosis: a complex interplay. Diabetes Metab 2012;38:193-204. https://doi.org/10.1016/j.diabet.2012.01.002
- Chinn RY, Diamond RD. Generation of chemotactic factors by Rhizopus oryzae in the presence and absence of serum: relationship to hyphal damage mediated by human neutrophils and effects of hyperglycemia and ketoacidosis. Infect Immun 1982;38:1123-9.
- Roden MM, Zaoutis TE, Buchanan WL, Knudsen TA, Sarkisova TA, Schaufele RL, et al. Epidemiology and outcome of zygomycosis: a review of 929 reported cases. Clin Infect Dis 2005;41:634-53. https://doi.org/10.1086/432579
- Chakrabarti A, Das A, Mandal J, Shivaprakash MR, George VK, Tarai B, et al. The rising trend of invasive zygomycosis in patients with uncontrolled diabetes mellitus. Med Mycol 2006;44:335-42. https://doi.org/10.1080/13693780500464930
- Spellberg B, Kontoyiannis DP, Fredricks D, Morris MI, Perfect JR, Chin-Hong PV, et al. Risk factors for mortality in patients with mucormycosis. Med Mycol 2012;50:611-8. https://doi.org/10.3109/13693786.2012.669502
- Llorente A, Perez-Valero I, García E, Heras I, Fraile V, García P, et al. Mortality risk factors in patients with zygomycosis: a retrospective and multicentre study of 25 cases. Enferm Infecc Microbiol Clin 2011;29:263-8. https://doi.org/10.1016/j.eimc.2010.09.008
- Pagano L, Offidani M, Fianchi L, Nosari A, Candoni A, Piccardi M, et al; GIMEMA (Gruppo Italiano Malattie EMatologiche dell'Adulto) Infection Program. Mucormycosis in hematologic patients. Haematologica 2004;89:207-14.
- Chamilos G, Lewis RE, Kontoyiannis DP. Delaying amphotericin B-based frontline therapy significantly increases mortality among patients with hematologic malignancy who have zygomycosis. Clin Infect Dis 2008;47:503-9. https://doi.org/10.1086/590004
- Rapidis AD. Orbitomaxillary mucormycosis (zygomycosis) and the surgical approach to treatment: perspectives from a maxillofacial surgeon. Clin Microbiol Infect 2009;15(Suppl 5):98-102.
- Gamaletsou MN, Sipsas NV, Roilides E, Walsh TJ. Rhino-orbital-cerebral mucormycosis. Curr Infect Dis Rep 2012;14:423-34. https://doi.org/10.1007/s11908-012-0272-6
- Groll AH, Giri N, Petraitis V, Petraitiene R, Candelario M, Bacher JS, et al. Comparative efficacy and distribution of lipid formulations of amphotericin B in experimental Candida albicans infection of the central nervous system. J Infect Dis 2000;182:274-82. https://doi.org/10.1086/315643
- Reed C, Bryant R, Ibrahim AS, Edwards J Jr, Filler SG, Goldberg R, et al. Combination polyene-caspofungin treatment of rhino-orbital-cerebral mucormycosis. Clin Infect Dis 2008;47:364-71. https://doi.org/10.1086/589857
피인용 문헌
- Combined Orofacial Aspergillosis and Mucormycosis: Fatal Complication of a Recurrent Paediatric Glioma-Case Report and Review of Literature vol.181, pp.9, 2013, https://doi.org/10.1007/s11046-016-0021-8
- La mucormycose en ORL. À propos de 4 observations vol.133, pp.2, 2013, https://doi.org/10.1016/j.aforl.2015.01.007
- Epidemiology, clinical features, diagnosis and treatment of cerebral mucormycosis in diabetic patients: A systematic review of case reports and case series vol.63, pp.12, 2020, https://doi.org/10.1111/myc.13187